Clearside Biomedi (CLSD)

$0.32 -0.03 (-8.61%)
Market Cap 26.06M
Revenue (ttm) 1.66M
Net Income (ttm) -34.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,069.28%
Debt to Equity Ratio 0.00
Volume 1,351,424
Avg Vol 5,568,396
Day's Range N/A - N/A
Shares Out 78.51M
Stochastic %K 52%
Beta 2.11
Analysts Sell
Price Target $4.00

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 270 3631
Fax: 678 270 4033
Address:
900 North Point Parkway, Suite 200, Alpharetta, United States
rando321456
rando321456 Feb. 4 at 5:17 AM
$CLSD The drama continues with the latest docket drop, god this is so pathetic.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 1 at 1:37 PM
$CLSD isn't there some data due from one of the partners in the next month or two?
1 · Reply
jbal
jbal Jan. 31 at 9:27 PM
$CLSD No surprises at the hearing. Merits of the claims weren't argued. HCR claimed CLSD surrepticiously transfered the royalties over the cap and this triggered a coc. Said they first learned of it from the SHB purchase agreement. (That was 1/9). CLSD disagrees that a CoC was triggered. Can't contnue auction because uncertainty will chill bidding. They first heard of HCR's CoC claim the morning of the auction (1/20). HCR objected to an accelerated schedule for arguements, wants 30 days. Says "the race here is to get on with an insider led stalking horse bid being promulgated by the debtor's chief medical officer". HCR's interests "are in the royalty sub being run effectively so that it can get the royalty streams that it has purchased. It has no other interest here other than getting the benefit of its investment". Hearing March 4th.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 31 at 5:46 PM
$CLSD anything material from fridays hearing ?
0 · Reply
Qora
Qora Jan. 30 at 5:41 AM
$CLSD So what’s going on with this one. HCR case still unresolved?
1 · Reply
buyandsold
buyandsold Jan. 28 at 10:16 PM
$CLSD i wish there was volume behind the price. I think we are a zero or will get over $5 if we hold through a good reorg. 50:50
0 · Reply
bio3jl23
bio3jl23 Jan. 26 at 4:21 PM
$CLSD we have to do ourself help . using whatever way to reach CLSD management and board direcotrs ( calls , emails and certified mails ) to request their follow their duty to have new auction but with re-organzation formart only !!!! we can adopt charlestown re-org bid as re-org stalking horse bidder as start . i believe there are lots of bio investors might interesting in this re-org. or at least management should negociate with Charlestwon capital for more investing ( but they can only have 44% around share because they have already 4.5% share share currently , it is legal requirement for not triggeribng C of C payment, for example CLSD can sell $5MILLIION for CLX-Ax to them with guarentee three years or five years later buyback with interest if CLX-AX NOT BE able to sellout for Charlestown profit , this mean secure more fund to maitain CLSD for three-four years. if any royalty bound assets ( aura and abbv ) got approval , that means CLSD no problem to have fund anymore,
0 · Reply
JaumeIII
JaumeIII Jan. 26 at 3:32 PM
$CLSD when does the bidding resume? Anyone know?
1 · Reply
bio3jl23
bio3jl23 Jan. 26 at 3:10 PM
$CLSD CLSD assets sales is dead way if no any pharmaceuticals join bidding fight, The only way which could achieve maximizing all shareholder interest is re-organization by injecting new fund necessary keeping CLSD maintaining its very basic function ( pay all patents maintaining fee ( domestic and international cost estimate 1 million per year, license fee to GA university 400k-500k per year and accounting and legal fee plus hiring few workers , estimate minimum 2millin per year ) maintaining “ zombie “ for at least 2-3 years ( 2028 aura first choroidal melanoma bel-sar topline data out and get approved , and expected 2029 ABBV-314 FOR GA would get approved )
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 26 at 3:04 PM
$CLSD looks like someone wanted out after reading the HCR supplement? we already knew they objected to the HK/SHB what do you guys think?
1 · Reply
Latest News on CLSD
No data available.
rando321456
rando321456 Feb. 4 at 5:17 AM
$CLSD The drama continues with the latest docket drop, god this is so pathetic.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 1 at 1:37 PM
$CLSD isn't there some data due from one of the partners in the next month or two?
1 · Reply
jbal
jbal Jan. 31 at 9:27 PM
$CLSD No surprises at the hearing. Merits of the claims weren't argued. HCR claimed CLSD surrepticiously transfered the royalties over the cap and this triggered a coc. Said they first learned of it from the SHB purchase agreement. (That was 1/9). CLSD disagrees that a CoC was triggered. Can't contnue auction because uncertainty will chill bidding. They first heard of HCR's CoC claim the morning of the auction (1/20). HCR objected to an accelerated schedule for arguements, wants 30 days. Says "the race here is to get on with an insider led stalking horse bid being promulgated by the debtor's chief medical officer". HCR's interests "are in the royalty sub being run effectively so that it can get the royalty streams that it has purchased. It has no other interest here other than getting the benefit of its investment". Hearing March 4th.
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 31 at 5:46 PM
$CLSD anything material from fridays hearing ?
0 · Reply
Qora
Qora Jan. 30 at 5:41 AM
$CLSD So what’s going on with this one. HCR case still unresolved?
1 · Reply
buyandsold
buyandsold Jan. 28 at 10:16 PM
$CLSD i wish there was volume behind the price. I think we are a zero or will get over $5 if we hold through a good reorg. 50:50
0 · Reply
bio3jl23
bio3jl23 Jan. 26 at 4:21 PM
$CLSD we have to do ourself help . using whatever way to reach CLSD management and board direcotrs ( calls , emails and certified mails ) to request their follow their duty to have new auction but with re-organzation formart only !!!! we can adopt charlestown re-org bid as re-org stalking horse bidder as start . i believe there are lots of bio investors might interesting in this re-org. or at least management should negociate with Charlestwon capital for more investing ( but they can only have 44% around share because they have already 4.5% share share currently , it is legal requirement for not triggeribng C of C payment, for example CLSD can sell $5MILLIION for CLX-Ax to them with guarentee three years or five years later buyback with interest if CLX-AX NOT BE able to sellout for Charlestown profit , this mean secure more fund to maitain CLSD for three-four years. if any royalty bound assets ( aura and abbv ) got approval , that means CLSD no problem to have fund anymore,
0 · Reply
JaumeIII
JaumeIII Jan. 26 at 3:32 PM
$CLSD when does the bidding resume? Anyone know?
1 · Reply
bio3jl23
bio3jl23 Jan. 26 at 3:10 PM
$CLSD CLSD assets sales is dead way if no any pharmaceuticals join bidding fight, The only way which could achieve maximizing all shareholder interest is re-organization by injecting new fund necessary keeping CLSD maintaining its very basic function ( pay all patents maintaining fee ( domestic and international cost estimate 1 million per year, license fee to GA university 400k-500k per year and accounting and legal fee plus hiring few workers , estimate minimum 2millin per year ) maintaining “ zombie “ for at least 2-3 years ( 2028 aura first choroidal melanoma bel-sar topline data out and get approved , and expected 2029 ABBV-314 FOR GA would get approved )
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 26 at 3:04 PM
$CLSD looks like someone wanted out after reading the HCR supplement? we already knew they objected to the HK/SHB what do you guys think?
1 · Reply
Qora
Qora Jan. 26 at 2:23 AM
$CLSD Anyone mind looping me in on what’s up? My understanding is that apart from the bidding we might just keep some diluted shares in a new company. Is that right?
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 23 at 6:43 PM
$CLSD did one of you guys just put a bid up for almost 50k shares? close to 1% of tso
1 · Reply
rando321456
rando321456 Jan. 23 at 3:16 AM
$CLSD What's especially damning imo is that this shell entity trying to buy the company put up 3 million dollars to justify to HCR that they can run the assets. It raises the question why not just run the company on the ~6 million the company had before pissing it all away on lawyers?
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 22 at 4:59 PM
$CLSD has the auction re started another bid or bids on the table?
1 · Reply
rando321456
rando321456 Jan. 22 at 4:09 AM
$CLSD As things stand I don't think Evoniks bid will be acceptable to HCR. I also think HCR will block the SHB, there may be some coordination between HCR and the adhoc group imo. If HCR is pushing for a COC payment then the path of least resistance is combining the reorg bid with Aura's bid for the residuals and manufacturing rights. Though depending on how much it costs to run the company without all these worthless parasites, the resulting entity may be able to keep Aura's residuals. Regardless of that Aura's flow throughs will still go to paying down HCR so not a total loss if they go. We could wind up with an empty company with 8.4 million and license deals for Avoralstat, Xipere, and RGX-314. I personally think Evoniks will wind up overbidding and working something out with HCR, we'll see.
2 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 21 at 3:41 PM
$CLSD Excellent article that nails exactly where CLSD stands right now. So if you want to update your CLSD knowledge or get acquainted with CLSD, this is a must read. https://everyticker.com/quote/CLSD/analysis/clearside-biomedical-s-scs-platform-paradox-a-valuable-technology-faces-binary-outcomes-in-bankruptcy-nasdaq-clsd
0 · Reply
jbal
jbal Jan. 21 at 2:57 PM
$CLSD Summary of the bids: Health Ocean (SHB): increased bid to $4.28M according to the terms in their original proposal. Aura: $3M for the residual royalties over the hard cap pertaining to Bel-Sar plus a $5M CDR for maunfacturing rights for the injecter upon FDA approval of Bel-Sar. Evonik: $4.8M generally matching the terms of the SHB, except HCR is responsible for paying the annual fee to Georgia Tech Charlestown Capital: $3.3M for 49% of CLSD. An additional $600K for 100% of CLS-AX. Values the enterprise at $7.33M. HCR: $4.9 credit bid against change of control payment, plus $100K. CLSD attorney disputed that there was a COC payment due HCR. Auction adhourned after a single round of bidding.
3 · Reply
buyandsold
buyandsold Jan. 21 at 2:34 PM
$CLSD is it still a possibility an equity committee is formed? If so I will write to the judge requesting it is not. I dont want to reduce distribution by paying them to review all docs going back years for a 7 figure bill. There could be no benefit, they cant create money, only burn it?
1 · Reply
rando321456
rando321456 Jan. 21 at 1:23 AM
$CLSD Per BCRX Avoralstat if we somehow get through this with equity interest: "Most likely when a deal materializes. Let me tell you where we are right now. We've got -- in the Phase I study, we've got 3 cohorts. We've completed the first cohort at a 100-microgram dose. That was by design, is really a safety dose. So we do not expect to see much efficacy from that. The next cohort goes to 250 micrograms and the third cohort goes to 500 micrograms. We just opened the IND in the U.S. So we're starting to enroll U.S. studies. Previously, it was just in Australia. And so we're confident that towards the middle of this year, we'll have a lot more data there. But you're likely to see the data more when we announce a deal."
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 21 at 1:17 AM
$CLSD have you guys seen a filing or docket yet? based on the numbers posted so far shareholders are looking at somewheres north of $1.50 per in the final analysis
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Jan. 20 at 10:26 PM
$CLSD how much are the current bids
1 · Reply
rando321456
rando321456 Jan. 20 at 10:16 PM
$CLSD Most likely outcome here is the reorg bid + Aura's bid for the residuals and manufacturing rights winning. HCR has made it clear they will challenge Health Ocean's bid validity.
2 · Reply